Revolution Medicines buyers will step in on weakness, says Stifel

Stifel expects buyers of Revolution Medicines (RVMD) to step into the stock on weakness after the Wall Street Journal reported that Merck (MRK) is no longer in discussions to acquire the company. Stifel would be surprised to see the stock settle meaningfully below $100 per share. This “M&A clearing event will be viewed as a buying opportunity for many sector specialists,” the analyst tells investors in a research note. The firm expects investor focus to shift now to Revolution’s “catalyst rich” 2026. It keeps a Buy rating on the shares with a $170 price target.